iBio, Inc.
As of Oct 22, 2026, iBio is in Stage 4, the downtrend phase, now in week 17 (since Jun 25, 2026). It closed at $0.78, 74.6% below its 52-week high and below its 200-day average, which is falling.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is IBIO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IBIO among Biotechnology281st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …281 | IBIO | Stage 4 · wk 17 | 33 | −37.6% |
iBio: quick answers
What stage is iBio in?
As of Oct 22, 2026, iBio (IBIO) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 25, 2026 and is in week 17. What the four stages mean
Is iBio in an uptrend?
No. iBio is in a Stage 4 downtrend. It trades 55.3% below its 200-day average, which is falling.
How far is iBio from its 52-week high?
iBio closed at $0.78 on Oct 22, 2026, 74.6% below its 52-week high of $3.07. Its 52-week low is $0.76.
How has iBio performed over the past year?
As of Oct 22, 2026, iBio is down 29.7% over the past year and down 61.4% so far in 2026.
Which sector and industry is iBio in?
iBio is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.